These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19340930)

  • 1. In silico platform for xenobiotics ADME-T pharmacological properties modeling and prediction. Part II: The body in a Hilbertian space.
    Jacob A; Pratuangdejkul J; Buffet S; Launay JM; Manivet P
    Drug Discov Today; 2009 Apr; 14(7-8):406-12. PubMed ID: 19340930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico platform for xenobiotics ADME-T pharmacological properties modeling and prediction. Part I: Beyond the reduction of animal model use.
    Huynh L; Masereeuw R; Friedberg T; Ingelman-Sundberg M; Manivet P
    Drug Discov Today; 2009 Apr; 14(7-8):401-5. PubMed ID: 19340929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying machine learning techniques for ADME-Tox prediction: a review.
    Maltarollo VG; Gertrudes JC; Oliveira PR; Honorio KM
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):259-71. PubMed ID: 25440524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico approaches for predicting ADME properties of drugs.
    Yamashita F; Hashida M
    Drug Metab Pharmacokinet; 2004 Oct; 19(5):327-38. PubMed ID: 15548844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural modulators of nonalcoholic fatty liver disease: Mode of action analysis and in silico ADME-Tox prediction.
    Al Sharif M; Alov P; Vitcheva V; Diukendjieva A; Mori M; Botta B; Tsakovska I; Pajeva I
    Toxicol Appl Pharmacol; 2017 Dec; 337():45-66. PubMed ID: 29056366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico ADME-Tox modeling: progress and prospects.
    Alqahtani S
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1147-1158. PubMed ID: 28988506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. truPK -- human pharmacokinetic models for quantitative ADME prediction.
    Subramanian K
    Expert Opin Drug Metab Toxicol; 2005 Oct; 1(3):555-64. PubMed ID: 16863461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Human Pharmacokinetics: Physiologically Based Pharmacokinetic Modeling and In Silico ADME Prediction in Early Drug Discovery.
    Shi J; Zha W
    Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):135-137. PubMed ID: 30136219
    [No Abstract]   [Full Text] [Related]  

  • 9. Predicting ADME properties in silico: methods and models.
    Butina D; Segall MD; Frankcombe K
    Drug Discov Today; 2002 Jun; 7(11):S83-8. PubMed ID: 12047885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational models for predicting the interaction with ABC transporters.
    Pinto M; Digles D; Ecker GF
    Drug Discov Today Technol; 2014 Jun; 12():e69-77. PubMed ID: 25027377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in predicting human ADME parameters in silico.
    Ekins S; Waller CL; Swaan PW; Cruciani G; Wrighton SA; Wikel JH
    J Pharmacol Toxicol Methods; 2000; 44(1):251-72. PubMed ID: 11274894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Silico Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics (ADME-PK): Utility and Best Practices. An Industry Perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development.
    Lombardo F; Desai PV; Arimoto R; Desino KE; Fischer H; Keefer CE; Petersson C; Winiwarter S; Broccatelli F
    J Med Chem; 2017 Nov; 60(22):9097-9113. PubMed ID: 28609624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting ADME properties and side effects: the BioPrint approach.
    Krejsa CM; Horvath D; Rogalski SL; Penzotti JE; Mao B; Barbosa F; Migeon JC
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):470-80. PubMed ID: 12951810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico prediction of ADME properties: are we making progress?
    Beresford AP; Segall M; Tarbit MH
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):36-42. PubMed ID: 14982146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gaussian processes: a method for automatic QSAR modeling of ADME properties.
    Obrezanova O; Csanyi G; Gola JM; Segall MD
    J Chem Inf Model; 2007; 47(5):1847-57. PubMed ID: 17602549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico techniques for the study and prediction of xenobiotic metabolism: a review.
    Kulkarni SA; Zhu J; Blechinger S
    Xenobiotica; 2005; 35(10-11):955-73. PubMed ID: 16393855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADME-Space: a new tool for medicinal chemists to explore ADME properties.
    Bocci G; Carosati E; Vayer P; Arrault A; Lozano S; Cruciani G
    Sci Rep; 2017 Jul; 7(1):6359. PubMed ID: 28743970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probabilistic prediction of the human CYP3A4 and CYP2D6 metabolism sites.
    Dapkunas J; Sazonovas A; Japertas P
    Chem Biodivers; 2009 Nov; 6(11):2101-6. PubMed ID: 19937844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico ADME prediction: data, models, facts and myths.
    Lombardo F; Gifford E; Shalaeva MY
    Mini Rev Med Chem; 2003 Dec; 3(8):861-75. PubMed ID: 14529504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-dimensional (2D) in silico models for absorption, distribution, metabolism, excretion and toxicity (ADME/T) in drug discovery.
    Khakar PS
    Curr Top Med Chem; 2010; 10(1):116-26. PubMed ID: 19929825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.